Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 1/20 | 0.38 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29966726 | 1.00 | GPR119 (0.44) | GPR119RIPK1CHRNA1CHRNB4CHRNA3 | |
| SCHEMBL30547538 | 1.00 | GPR119 (0.44) | GPR119RIPK1CHRNA1CHRNB4CHRNA3 | |
| SCHEMBL29048251 | 1.00 | GPR119 (0.44) | GPR119RIPK1CHRNA1CHRNB4CHRNA3 | |
| SCHEMBL25817662 | 1.00 | GPR119 (0.44) | GPR119RIPK1CHRNA1CHRNB4CHRNA3 | |
| SCHEMBL30339751 | 1.00 | GPR119 (0.44) | GPR119RIPK1CHRNA1CHRNB4CHRNA3 | |
| SCHEMBL30338978 | 0.91 | GPR119 (0.39) | GPR119RIPK1CHRNA1CHRNB4CHRNA3 | |
| SCHEMBL25303343 | 0.88 | GPR119 (0.49) | GPR119RIPK1NSD2 | |
| SCHEMBL30338800 | 0.88 | GPR119 (0.49) | GPR119RIPK1NSD2 | |
| SCHEMBL25818880 | 0.87 | GPR119 (0.45) | GPR119RIPK1 | |
| SCHEMBL25816609 | 0.86 | GPR119 (0.44) | GPR119RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| CN-108602809-B | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1(RIPK 1) | 戴纳立制药公司 | 2022-09-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | GPR119 420/4885RIPK1 1/4885CHRNA1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.